KR20240099266A - 항문 고등급편평상피내병변(hsil)을 치료하기 위한 조성물 및 방법 - Google Patents

항문 고등급편평상피내병변(hsil)을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20240099266A
KR20240099266A KR1020247015465A KR20247015465A KR20240099266A KR 20240099266 A KR20240099266 A KR 20240099266A KR 1020247015465 A KR1020247015465 A KR 1020247015465A KR 20247015465 A KR20247015465 A KR 20247015465A KR 20240099266 A KR20240099266 A KR 20240099266A
Authority
KR
South Korea
Prior art keywords
seq
nucleotide sequence
nucleic acid
fragment
sequence encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247015465A
Other languages
English (en)
Korean (ko)
Inventor
지안 얀
종 요셉 김
프라카쉬 부얀
제프리 스콜닉
Original Assignee
이노비오 파마수티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노비오 파마수티컬즈, 인크. filed Critical 이노비오 파마수티컬즈, 인크.
Publication of KR20240099266A publication Critical patent/KR20240099266A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247015465A 2021-10-22 2022-10-21 항문 고등급편평상피내병변(hsil)을 치료하기 위한 조성물 및 방법 Pending KR20240099266A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163270929P 2021-10-22 2021-10-22
US63/270,929 2021-10-22
PCT/US2022/078551 WO2023070109A1 (en) 2021-10-22 2022-10-21 Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil)

Publications (1)

Publication Number Publication Date
KR20240099266A true KR20240099266A (ko) 2024-06-28

Family

ID=86059748

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247015465A Pending KR20240099266A (ko) 2021-10-22 2022-10-21 항문 고등급편평상피내병변(hsil)을 치료하기 위한 조성물 및 방법

Country Status (10)

Country Link
US (1) US20230233659A1 (https=)
EP (1) EP4419138A4 (https=)
JP (1) JP2024539188A (https=)
KR (1) KR20240099266A (https=)
CN (1) CN118382457A (https=)
AU (1) AU2022371672A1 (https=)
CA (1) CA3235779A1 (https=)
CO (1) CO2024006161A2 (https=)
MX (1) MX2024004878A (https=)
WO (1) WO2023070109A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58080B1 (sr) * 2014-11-04 2019-02-28 Janssen Vaccines & Prevention Bv Terapeutske vakcine protiv hpv16
JP6470872B2 (ja) * 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
WO2018209322A1 (en) * 2017-05-11 2018-11-15 Inovio Pharmaceuticals, Inc. Clinical and immunologic biomarkers for regression of high grade cervical dysplasia and clearance of hpv16 and hpv18 infection after immunotherapy
WO2021202949A2 (en) * 2020-04-02 2021-10-07 Inovio Pharmaceuticals, Inc. Compositions and methods for treating vulvar dysplasia

Also Published As

Publication number Publication date
US20230233659A1 (en) 2023-07-27
WO2023070109A1 (en) 2023-04-27
EP4419138A4 (en) 2026-03-04
AU2022371672A1 (en) 2024-05-16
JP2024539188A (ja) 2024-10-28
EP4419138A1 (en) 2024-08-28
MX2024004878A (es) 2024-07-15
CO2024006161A2 (es) 2024-06-27
CA3235779A1 (en) 2023-04-27
CN118382457A (zh) 2024-07-23

Similar Documents

Publication Publication Date Title
KR101652764B1 (ko) 인간 파필로마 바이러스에 대한 개선된 백신 및 이것을 사용하는 방법
KR102742526B1 (ko) 암 백신 및 이를 이용하는 치료 방법
JP4805511B2 (ja) Ｈｉｖに対する免疫応答における改善、または免疫応答に関する改善
KR102581951B1 (ko) B형 간염 바이러스 코어 단백질 및 표면 항원 단백질 및 이를 포함하는 백신
JP6445523B2 (ja) 生体分子アジュバントを含むワクチン
KR101891195B1 (ko) 공통 항원 구성체 및 이것으로부터 만들어진 백신 및 말라리아를 치료하기 위한 이것의 사용방법
TW202229556A (zh) 針對SARS-CoV-2之改良型DNA疫苗
CN115135340A (zh) 针对非洲猪瘟病毒的疫苗及其使用方法
JP2025158979A (ja) 再発性呼吸器乳頭腫症のためのワクチン及びそれを使用する方法
JP2026031543A (ja) 再発性呼吸器乳頭腫症のための改善されたワクチンおよびそれを使用するための方法
US20230233659A1 (en) Compositions and methods for treating anal high-grade squamous intraepithelial lesion (hsil)
EP2968496A2 (en) Synthetic immunogens for prophylaxis or treatment of tuberculosis
US12357683B2 (en) Vaccines against Nipah virus, and methods of using same
HK1262085A1 (en) Cancer vaccines and methods of treatment using the same
US20220054620A1 (en) Vaccines against powassan virus, and methods of using same
HK40053340A (en) Vaccines against nipah virus, and methods of using same
KR20200096959A (ko) Lemd1을 표적화하는 암 백신 및 이의 용도
HK1164688A (en) Improved vaccines for human papilloma virus and methods for using the same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000